Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:7427's PB Ratio is ranked worse than 77.36% of 1228
companies
in the Biotechnology industry
Industry Median: 2.85
vs ROCO:7427: 6.42
During the past 12 months, Great Novel Therapeutics Biotech & Medicals's average Book Value Per Share Growth Rate was -18.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.60% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 62.30% per year. The lowest was 3.10% per year. And the median was 43.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Great Novel Therapeutics Biotech & Medicals PB Ratio Related Terms
Great Novel Therapeutics Biotech & Medicals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals PB Ratio Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals PB Ratio vs Biotechnology Industry
Great Novel Therapeutics Biotech & Medicals PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a PB Ratio of 6.43 as of Aug. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. This is 66% above median its historical median of 3.88. Over the past decade, Great Novel Therapeutics Biotech & Medicals' PB Ratio has ranged from 2.07 to 19.38. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #950 out of 1228 companies in the Biotechnology industry, placing it in the top 77.4%.
Is Great Novel Therapeutics Biotech & Medicals' PB Ratio too high?
Great Novel Therapeutics Biotech & Medicals' current PB Ratio of 6.43 is 66% above median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 19.38. The Biotechnology industry median PB Ratio is 2.85. Great Novel Therapeutics Biotech & Medicals' value of 6.43 is 125.6% above this industry median. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #950 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #950 out of 1228 companies for PB Ratio. This places Great Novel Therapeutics Biotech & Medicals in the lower half of its industry. The industry median PB Ratio is 2.85. Great Novel Therapeutics Biotech & Medicals' value of 6.43 is 125.6% above this benchmark. Historically, Great Novel Therapeutics Biotech & Medicals' own PB Ratio has ranged from 2.07 to 19.38 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 2.85, Great Novel Therapeutics Biotech & Medicals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.85, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Great Novel Therapeutics Biotech & Medicals's current PB Ratio of 6.43 is 125.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Novel Therapeutics Biotech & Medicals's current PB Ratio is 6.43, which is 66% above median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.88, compared to a current price of NT$72.20 — trading 179% above its estimated fair value. The current PB Ratio is 6.43, which is 66% above median its 10-year median of 3.88 and 125.6% above the Biotechnology industry median of 2.85. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current PB Ratio is 6.43 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$72.20 is trading 179% above its estimated GF Value™ of NT$25.88.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
PB Ratio: 6.43 (66% above median its 10-year median of 3.88)
GF Value™: NT$25.88 vs. price of NT$72.20 (179% above fair value)
Industry Position: 125.6% above the Biotechnology median (#950 of 1228)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
42GF Score
Get the complete analysis for ROCO:7427
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
